Skip to main content
SpringerLink
Log in

Hemmstoffe des Renin-Angiotensin-Systems

  • Chapter
Arzneiverordnungs-Report 2012

  • 1393 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 59.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • ACTIVE I Investigators, Yusuf S, Healey JS, Pogue J., Chrolavicius S et al (2011): Irbesartan in patients with atrial fibrillation. N Engl J Med 364: 928-938.

    Article  Google Scholar 

  • Ahmed AK, Kamath NS, El Kossi M, El Nahas AM (2010): The impact of stopping inhibitors of the renin-angiotensin system in patients with advanced chronic kidney disease. Nephrol Dial Transplant 25: 3977-3982.

    Article  PubMed  CAS  Google Scholar 

  • Anlauf M (2006): Beurteilung von Therapien mit der „number needed to treat". Dtsch Ärztebl 103: A3254-A3258.

    Google Scholar 

  • Arzneimittelkommission der Deutschen Ärzteschaft (2004): Empfehlungen zur Therapie der arteriellen Hypertonie. 2. Auflage, Arzneiverordnung in der Praxis, Band 31, Sonderheft 2 (Therapieempfehlungen), Internet: www.akdae.de/35/74_ Hypertonie_2004_2Auflage.pdf

  • Bakris GL, Sarafidis PA, Weir MR, Dahlöf B et al for the ACCOMPLISH Trial investigators (2010): Renal outcomes with diff erent fixed-dose combination therapies in pati- ents with hypertension at high risk for cardiovascular events (ACCOMPLISH): a pre- specified secondary analysis of a randomised controlled trial. Lancet 375: 1173-1181.

    Article  PubMed  CAS  Google Scholar 

  • Bangalore S, Kumar S, Kjeldsen SE, Makani H et al (2011): Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324 168 partici- pants from randomised trials. Lancet Oncol 12: 65-82.

    Article  PubMed  CAS  Google Scholar 

  • Barnett AH, Bain SC, Bouter P, Karlberg B et al (2004): Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 351: 1952-1961.

    Article  PubMed  CAS  Google Scholar 

  • Bhaskaran K, Douglas I, Evans S, van Staa T et al (2012): Angiotensin receptor blockers and risk of cancer: cohort study among people receiving antihypertensive drugs in UK General Practice Research Database. BMJ 344:e2697.

    Article  Google Scholar 

  • Beckett NS, Peters R, Fletcher AE, Staessen JA et al for the HYVET Study Group (2008): Treatment of hypertension in patients 80 years of age or older. N Engl J Med 358: 1887-1898.

    Article  PubMed  CAS  Google Scholar 

  • Beckett N, Peters R, Tuomilehto J, Swift C et al for the HYVET Study Group (2012): Immediate and late benefits of treating very elderly people with hypertension: results from active treatment extension to Hypertension in the Very Elderly randomised controlled trial. BMJ 344: 1-10.

    Google Scholar 

  • Blood Pressure Lowering Treatment Trialists' Collaboration (2000): Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of pros- pectively designed overviews of randomised trials. Lancet 356: 1955-1964.

    Article  Google Scholar 

  • Blood Pressure Lowering Treatment Trialists' Collaboration (2007): Blood Pressure de- pendent and independent effects of agents that inhibit the renin-angiotensin system. J. Hypertension 25: 951-958.

    Article  Google Scholar 

  • Brown MJ (2008): Aliskiren. Circulation 118: 773-784.

    Article  PubMed  CAS  Google Scholar 

  • Burgess E, Muirhead N, Rene de Cotret P, Chiu A et al; SMART (Supra Maximal Atacand Renal Trial) Investigators (2009): Supramaximal dose of candesartan in proteinuric renal disease. J Am Soc Nephrol. 20: 893-900.

    Article  PubMed  CAS  Google Scholar 

  • Casas JP, Chua W, Loukogeorgakis S, Vallance P, Smeeth L, Hingorani AD, MacAllister RJ (2005): Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 366: 2026-2033.

    Article  PubMed  CAS  Google Scholar 

  • Cleland JG, Tendera M, Adamus J, Freemantle et al (2006): The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J. 27: 2338-2345.

    Article  PubMed  CAS  Google Scholar 

  • Cohn JN, Tognoni G for the Valsartan Heart Failure Trial Investigators (2001): A rando- mized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345: 1667-1675.

    Article  PubMed  CAS  Google Scholar 

  • CONSENSUS Trial Study Group (1987): Effects of enalapril on mortality in severe con- gestive heart failure: Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 316: 1429-1435.

    Article  Google Scholar 

  • Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, Faire U et al for The LIFE Study Group (2002): Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359: 995-1003.

    Article  PubMed  Google Scholar 

  • Dahlöf B, Sever PS, Neil R, Poulter NP, Wedel H (2005): Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendrofumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicen- tre randomised controlled trial. Lancet 366: 895-906.

    Article  PubMed  Google Scholar 

  • Davis BD, Piller LB, Cutler JA, Curt Furberg C et al (2006): Role of Diuretics in the Prevention of Heart Failure. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Circulation 113: 2201-2210.

    Article  PubMed  CAS  Google Scholar 

  • Davis BR, Kostis JB, Simpson LM, Black HR et al (ALLHAT, 2008): Heart failure with preserved and reduced left ventricular ejection fraction in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Circulation 118: 2259-2267.

    Article  PubMed  CAS  Google Scholar 

  • Dickstein K, Kjekshus J, and the OPTIMAAL Steering Committee, for the OPTIMAAL Study Group (2002): Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised tri- al. Lancet 360: 752-760.

    Article  PubMed  CAS  Google Scholar 

  • Elliott WJ, Meyer PM (2007): Incident diabetes in clinical trials of antihypertensive drugs:a network meta-analysis. Lancet 369: 201-207.

    Article  PubMed  CAS  Google Scholar 

  • Flather MD, Yusuf S, Kober L, Pfeffer M et al (2000): Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. Lancet 355: 1575-1581.

    Article  PubMed  CAS  Google Scholar 

  • GISSI-AF Investigators, Disertori M, Latini R, Barlera S, Franzosi MG et al (2009): Valsartan for prevention of recurrent atrial fibrillation.N Engl J Med. 360: 1606-17.

    Article  Google Scholar 

  • Granger CB, McMurray JJV, Yusuf S, Held P et al (2003): Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 362: 772-776.

    Article  PubMed  CAS  Google Scholar 

  • Granger CB, McMurray JJV, Yusuf S, Held P et al (2003): Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 362: 772-776.

    Article  PubMed  CAS  Google Scholar 

  • Grimm RH, Davis BR, Piller LB, Cutler JA et al ALLHAT Collaborative Research Group. (2009): Heart failure in ALLHAT: did blood pressure medication at study entry influ- ence outcome? J Clin Hypertens (Greenwich).11: 466-474.

    Article  CAS  Google Scholar 

  • Haller H, Ito S, Izzo JL Jr, Januszewicz A et al ROADMAP Trial Investigators (2011): Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med. 364: 907-917.

    Article  PubMed  CAS  Google Scholar 

  • Heerspink HL, de Zeeuw D (2010): Composite renal endpoints: was ACCOMPLISH ac- complished? Lancet 375: 1140-1142.

    Article  PubMed  Google Scholar 

  • Hermida RC, Ayala DE, Mojon A, Fernandez JR (2011): Bedtime dosing of antihypertensi- ve medications reduces cardiovascular risk in CKD. J Am Soc Nephrol. 22: 2313-2321.

    Article  PubMed  Google Scholar 

  • Imai E, Chan JC, Ito S, Yamasaki T, et al for the ORIENT investigators (2011): Effects of ol- mesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropa- thy: a multicentre, randomised, placebo-controlled study. Diabetologia 54: 2978-2986.

    Article  PubMed  CAS  Google Scholar 

  • Jamerson K, Weber MA, Bakris GL, Dahlöf B et al ACCOMPLISH Trial Investigators (2008): Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high- risk patients. N Engl J Med. 359: 2417-2428.

    Article  PubMed  CAS  Google Scholar 

  • Jamerson KA, Devereux R, Bakris GL, Dahlöf B et al (2011): Efficacy and duration of benazepril plus amlodipine or hydrochlorothiazide on 24-hour ambulatory systolic blood pressure control. Hypertension. 57: 174-179.

    Article  PubMed  CAS  Google Scholar 

  • Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, Hua T, Laragh J, McInnes GT, Mitchell L, Plat F, Schork A, Smith B, Zanchetti A; VALUE trial group (2004): Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 363: 2022-2031.

    Article  PubMed  CAS  Google Scholar 

  • Julius S, Nesbitt SD, Egan BM. for the Trial of Preventing Hypertension (TROPHY) Study Investigators (2006): Feasibility of treating prehypertension with an angiotensin-re- ceptor blocker. N Engl J Med. 354: 1685-1697.

    Article  PubMed  CAS  Google Scholar 

  • Kassenärztliche Bundesvereinigung (2008): Wirkstoff aktuell. Aliskiren (Rasilez®). Internet: www.kbv.de/publikationen/116.html

  • Kunz R, Friedrich C, Wolbers M, Mann JFE (2008): Meta-analysis: Effect of monotherapy and combination therapy with inhibitors of the renin-angiotensin system on protein- uria in renal disease. Ann Intern Med 148: 30-48.

    PubMed  Google Scholar 

  • Laverman GD, Navis G, Henning RH, de Jong D, de Zeeuw D (2002): Dual renin-angio- tensin system blockade at optimal doses for proteinuria. Kidney Int 62: 1020-1025.

    Article  PubMed  CAS  Google Scholar 

  • Levy BI (2004): Can angiotensin II Type 2 receptors have deleterious effects in cardiovascular disease? Circulation 109: 8-13.

    Article  PubMed  Google Scholar 

  • Lewis EJ, Hunsicker LG, Bain RP, Rohde RD for the Collaborative Study Group (1993): The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 329: 1456-1462.

    Article  PubMed  CAS  Google Scholar 

  • Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B et al for the SCOPE Study Group (2003): The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 21: 875-886.

    Article  PubMed  CAS  Google Scholar 

  • Lüders S, Schrader J, Berger J, Unger T, Zidek W, Böhm M, Middeke M, Motz W, Lübcke C, Gansz A, Brokamp L, Schmieder RE, Trenkwalder P, Haller H, Dominiak P; PHARAO study group (2008): The PHARAO study: prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure - a prospective, randomized, controlled prevention trial of the German Hypertension League. J Hypertens 26: 1487-1496.

    Article  PubMed  Google Scholar 

  • Malacco E, Santonastaso M, Vari NA, Gargiulo A, Spagnuolo V, Bertocchi F, Palatini P; Blood Pressure Reduction and Tolerability of Valsartan in Comparison with Lisinopril Study (2004): Comparison of valsartan 160 mg with lisinopril 20 mg, given as monotherapy or in combination with a diuretic, for the treatment of hypertension: the Blood Pressure Reduction and Tolerability of Valsartan in Comparison with Lisinopril (PREVAIL) study. Clin Ther 26: 855-865.

    Article  PubMed  CAS  Google Scholar 

  • Mann JF, Ritz E, Kunz R (2006): Renoprotective effects of renin-angiotensin-system inhibitors. Lancet 367: 900.

    Article  PubMed  Google Scholar 

  • Mann JFE, Schmieder RE, McQueen M, Dyal L et al on behalf of the ONTARGET investigators (2008): Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 372: 547-553.

    Article  PubMed  CAS  Google Scholar 

  • Mann JFE, Schmieder RE, Dyal L, McQueen MJ et al (2009): Effect of telmisartan on renal outcomes: a randomized trial. Ann Intern Med 151: 1-10, W1-2.

    PubMed  Google Scholar 

  • Maschio G, Albert D, Ganin G, Locatelli F, Mann JFE et al (1996): Effect of the angio- tensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 334: 939-945.

    Article  PubMed  CAS  Google Scholar 

  • Massie BM, Carson PE, McMurray JJ, Komajda M, et al I-PRESERVE Investigators (2008): Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 359: 2456-2467.

    Article  PubMed  CAS  Google Scholar 

  • McMurray JJV, Östergren J, Swedberg K, Granger CB et al (2003): Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking an- giotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 362: 767-771.

    Article  PubMed  CAS  Google Scholar 

  • McMurray JJ, Abraham WT, Dickstein K, Kober L et al (2012): Aliskiren, ALTITUDE, and the implications for ATMOSPHERE. Eur J Heart Fail. 14: 341-343.

    Article  PubMed  Google Scholar 

  • Mogensen CE, Neldam S, Tikkanen I, Oren S, Viskoper R, Watts RW, Cooper ME (2000): Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the Candesartan And Lisinopril Microalbuminuria (CALM) Study. Brit Med J 321: 1440-1444.

    Article  PubMed  CAS  Google Scholar 

  • National Collaborating Centre for Chronic Conditions (2006): Hypertension: management of hypertension in adults in primary care: partial update. London: Royal College of Physicians. Internet: http://guidance.nice. org.uk/CG34/guidance/pdf/English.

  • National Institutes of Health (2010): Clinicaltrials.gov trial webpage for ORIENT trial. Internet: www.clinicaltrials.gov/ct2/show/NCT00141453?term=0RIENT+olmesartan&rank=1 (Zugang 16.5.2011).

  • Oghlakian GO, Sipahi I, Fang JC (2011): Treatment of heart failure with preserved ejection fraction: have we been pursuing the wrong paradigm? Mayo Clin Proc. 86: 531-539.

    Article  PubMed  Google Scholar 

  • Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK; AVOID Study Investigators (2008): Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 358: 2433-2446.

    Article  PubMed  CAS  Google Scholar 

  • Pfeffer MA, McMurray JJV, Velazquez EJ, Rouleau J-L et al for the Valsartan in Acute Myocardial Infarction Trial Investigators (2003a): Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 349: 1893-1906.

    Article  CAS  Google Scholar 

  • Pfeffer MA, Swedberg K, Granger CB, Held P et al (2003b): Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 362: 559-766.

    Google Scholar 

  • Pitt B, Poole-Wilson PA, Segal R, Martinez FA et al (2000): Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study ELITE II. Lancet 355: 1582-1587.

    Article  PubMed  CAS  Google Scholar 

  • Pitt B (2004): ACE inhibitors for patients with vascular disease without left ventricular dysfunction - may they rest in PEACE? N Engl J Med 351: 2115-2117.

    Article  PubMed  CAS  Google Scholar 

  • PROGRESS Collaborative Group (2001): Randomised trial of a perindopril-based blood- pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 358: 1033-1041.

    Article  Google Scholar 

  • Rector TS, Carson PE, Anand IS, McMurray JJ et al for I-PRESERVE Trial investigators (2012): Assessment of long-term effects of irbesartan on heart failure with preserved ejection fraction as measured by the minnesota living with heart failure questionnaire in the irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial. Circ Heart Fail. 5: 217-225.

    Article  PubMed  CAS  Google Scholar 

  • Ruggenenti P, Fassi A, Ilieva AP, Bruno S, Iliev IP, Brusegan V, Rubis N, Gherardi G, Arnoldi F, Ganeva M, Ene-Iordache B, Gaspari F, Perna A, Bossi A, Trevisan R, Dodesini AR, Remuzzi G; Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators (2004): Preventing microalbuminuria in type 2 diabetes. N Engl J Med 351: 1941-1951.

    Article  PubMed  CAS  Google Scholar 

  • Sandset EC, Bath PM, Boysen G, Jatuzis D et al (2011) The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial. Lancet 377: 741-750.

    Article  PubMed  CAS  Google Scholar 

  • Saunders E, Weir MR, Kong BW, Hollifield J, Gray J, Vertes V et al (1990): A comparison of the efficacy and safety of a beta-blocker, a calcium channel blocker, and a converting enzyme inhibitor in hypertensive blacks. Arch Intern Med 150: 1707-1713.

    Article  PubMed  CAS  Google Scholar 

  • Schmieder RE, Klingbeil AU, Fleischmann EH, Veelken R, Delles C (2005): Additional antiproteinuric effect of ultrahigh dose candesartan: a double-blind, randomized, pro- spective study. J Am Soc Nephrol. 16: 3038-3045.

    Article  PubMed  CAS  Google Scholar 

  • Schmieder RE, Hilgers KF, Schlaich MP, Schmidt MW (2007): Renin angiotensin system and cardiovascular risk. Lancet 369: 1208-1219.

    Article  PubMed  CAS  Google Scholar 

  • Schneider MP, Hua TA, Böhm M, Wachtell K et al (2010): Prevention of atrial fibrillati- on by Renin-Angiotensin system inhibition a meta-analysis. J Am Coll Cardiol. 55: 2299-2307.

    Article  PubMed  Google Scholar 

  • Schrader J, Luders S, Kulschewski A, et al (2003): The ACCESS Study: evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors. Stroke 234: 1699-703.

    Article  Google Scholar 

  • Schrader J, Lüders S, Kulschewski A, Hammersen F et al for the MOSES Study Group (2005): Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention. Principal results of a prospective randomized controlled study (MOSES). Stroke 36: 1218-1226.

    Article  PubMed  CAS  Google Scholar 

  • Scottish Medicines Consortium (2009): Aliskiren, 150mg and 300mg film-coated tablets (Rasilez®) No. (462/08), Novartis Pharmaceuticals UK Ltd. Internet: www.scottish- medicines.org.uk/smc/files/aliskiren%20(Rasilez)% 20FINAL%20DEC%2008%20for%20website.pdf

  • Sipahi I, Debanne SM, Rowland DY, Simon DI, Fang JC (2010): Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials. Lancet Oncol. 2010 Jun 11. [Epub ahead of print].

    Google Scholar 

  • Svensson P, de Faire U, Sleight P, Yusuf S, Jan Östergren J (2001): Comparative effects of ramipril on ambulatory and office blood pressures. A HOPE substudy. Hypertension 38: e28-e32.

    Article  PubMed  CAS  Google Scholar 

  • The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2002): Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288: 2981-2997.

    Article  Google Scholar 

  • The DREAM Trial Investigators (2006): Effect of ramipril on the incidence of diabetes. N Engl J Med 355: 1551-1562.

    Article  Google Scholar 

  • The EURopean trial On reduction of cardiac events with Perindopril in stable corona- ry Artery disease Investigators (2003): Efficacy of perindopril in reduction of car- diovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 362: 782-788.

    Article  Google Scholar 

  • The GISEN Group (1997): Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 349: 1857-1863.

    Article  Google Scholar 

  • The Heart Outcomes Prevention Evaluation (HOPE) Study Investigators (2000): Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 342: 145-153.

    Article  Google Scholar 

  • The Indian Polycap Study (TIPS) (2009): Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, doubleblind, randomised trial. Lancet 373: 1341-1351.

    Article  Google Scholar 

  • The ONTARGET Investigators (2008): Telmisartan, ramipril or both in patients at high risk for vascular events. N Engl J Med 358: 1547-1559.

    Article  Google Scholar 

  • The Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators (2008): Effects of the angiotensin-re- ceptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 372: 1174-1183.

    Article  Google Scholar 

  • van Vark LC, Bertrand M, Akkerhuis KM, Brugts JJ et al (2012): Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158 998 patients. Eur Heart J. Apr 17. [Epub ahead of print].

    Google Scholar 

  • Verma S, Strauss M (2004): Angiotensin receptor blockers and myocardial infarction. These drugs may increase myocardial infarction - and patients may need to be told. BMJ 329: 1248-1249.

    Article  PubMed  Google Scholar 

  • Wachtell K, Hornestam B, Lehto M, Slotwiner DJ et al (2005a): Cardiovascular morbi- dity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol. 45: 705-711.

    Article  Google Scholar 

  • Wachtell K, Lehto M, Gerdts E, Olsen MH et al (2005b): Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol. 45: 712-719.

    Article  CAS  Google Scholar 

  • Wald NJ, Law MR (2003) A strategy to reduce cardiovascular disease by more than 80%. BMJ 326: 1419-1424.

    Article  PubMed  CAS  Google Scholar 

  • White HD (2003): Commentary. Candesartan and heart failure: the allure of CHARM. Lancet 362: 754-755.

    Article  PubMed  Google Scholar 

  • Wing LMH, Reid MC, Ryan P, Beilin LJ et al for the Second Australian National Blood Pressure Study Group (2003): A comparison of outcomes with angiotensin-conver- ting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 348: 583-592.

    Article  PubMed  CAS  Google Scholar 

  • Yusuf S (2002): From the HOPE to the ONTARGET and the TRANSCEND studies: chal- lenges in improving prognosis. Am J Cardiol 89 (2A): 18A-25A.

    Article  PubMed  Google Scholar 

  • Yusuf S, Pfeffer MA, Swedberg K, Granger CB et al (2003): Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 362: 777-781.

    Article  PubMed  CAS  Google Scholar 

  • Yusuf S, Diener HC, Sacco RL, Cotton D, Ounpuu S for the PRoFESS Study Group (2008): Telmisartan to prevent recurrent stroke and cardiovascular Events. N Engl J Med 359: 1225-1237.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Friedrich-Plettke-Weg 12, 27570, Bremerhaven

    Prof. Dr. med. Manfred Anlauf

Authors
  1. Prof. Dr. med. Manfred Anlauf
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Medizin Verlag Berlin, Heidelberg

About this chapter

Cite this chapter

Anlauf, M. (2012). Hemmstoffe des Renin-Angiotensin-Systems. In: Arzneiverordnungs-Report 2012. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-29242-2_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-29242-2_5

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-29241-5

  • Online ISBN: 978-3-642-29242-2

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation